Analysis of the safety and effectiveness of antithrombotic prophylaxis after elective total knee and hip arthroplasty: a prospective single-center real-world study
- Authors: Okisheva E.А.1, Trushina O.I.1, Madoyan M.D.1, Fidanyan S.E.1, Solonina A.D.1, Zhidilyaev A.V.1, Lychagin A.V.1, Fomin V.V.1
-
Affiliations:
- Sechenov First Moscow State Medical University (Sechenov University)
- Issue: Vol 97, No 7 (2025)
- Pages: 550-555
- Section: Original articles
- URL: https://journals.rcsi.science/0040-3660/article/view/314002
- DOI: https://doi.org/10.26442/00403660.2025.07.203279
- ID: 314002
Cite item
Full Text
Abstract
Aim. To evaluate the safety and effectiveness of various antithrombotic prophylaxis regimens after elective total knee arthroplasty (TKA) and elective total hip arthroplasty (THA).
Materials and methods. Medical history, information about concomitant diseases and previously prescribed drug therapy was recorded in all participants. Subsequently, a prospective observation was performed to record specific antithrombotic drugs and the duration of their use after surgery, patient compliance with the rehabilitation regimen, all cases of thrombosis and bleeding; all patients were contacted by phone 1 and 3 months after surgery.
Results. The study population included 271 males (34.7%) and 511 females (65.3%). 332 (42.5%) patients underwent THA and 450 (57.5%) patients underwent TKA. In the perioperative period, 769 patients (98.3%) received fraxiparine monotherapy as antithrombotic prophylaxis, and 13 (1.7%) patients received fraxiparine in combination with an antiplatelet agent due to previous percutaneous coronary intervention or very high cardiac risk. Within 1 month after surgery, 31 (4.0%) patients did not take any anticoagulants despite the prescriptions, 20 (2.6%) patients used aspirin instead of the prescribed anticoagulants. Other patients received direct oral anticoagulants (dabigatran, rivaroxaban, or apixaban) or warfarin as prescribed; among them 73 (9.3%) patients received concomitant antiplatelet agents. Seven (0.9%) patients used three anticoagulants concomitantly. During the first month after surgery, 9 cases (1.2%) of deep vein thrombosis were recorded (5 patients took no anticoagulants, another 4 participants were not compliant with the rehabilitation regimen). 5 (0.6%) cases of epistaxis, 4 (0.5%) cases of hemorrhoidal bleeding and 2 (0.2%) cases of hematoma in the surgical area were reported. All cases of thrombosis and bleeding were mild and resolved spontaneously. No statistically significant differences in the incidence of adverse events were found between different anticoagulant therapy regimens.
Conclusion. In a cohort of real-world patients undergoing elective TKA or THA, the differences between the effectiveness and safety of various anticoagulant prophylaxis regimens were not statistically significant. The incidence of thrombosis was low, and these complications were mainly reported in non-compliant patients. The incidence of bleeding in patients taking anticoagulants with antiplatelet agents was not elevated, however, the size of this subpopulation is small and does not allow to perform a significant assessment of the safety of this treatment regimen. Based on the findings, it is reasonable to develop additional methods to improve patient compliance in order to reduce the frequency of medication errors and decrease the incidence of possible complications.
Full Text
##article.viewOnOriginalSite##About the authors
Elena А. Okisheva
Sechenov First Moscow State Medical University (Sechenov University)
Author for correspondence.
Email: e.okisheva@gmail.com
ORCID iD: 0000-0003-2977-7203
доц. каф. факультетской терапии №1 Института клинической медицины им. Н.В. Склифосовского
Russian Federation, MoscowOlga Iu. Trushina
Sechenov First Moscow State Medical University (Sechenov University)
Email: e.okisheva@gmail.com
ORCID iD: 0000-0002-5820-1759
д-р мед. наук, проф. каф. факультетской терапии №1 Института клинической медицины им. Н.В. Склифосовского
Russian Federation, MoscowMaria D. Madoyan
Sechenov First Moscow State Medical University (Sechenov University)
Email: e.okisheva@gmail.com
ORCID iD: 0000-0002-0167-5785
студентка Института клинической медицины им. Н.В. Склифосовского
Russian Federation, MoscowSvetlana E. Fidanyan
Sechenov First Moscow State Medical University (Sechenov University)
Email: e.okisheva@gmail.com
ORCID iD: 0000-0001-9592-3542
студентка Института клинической медицины им. Н.В. Склифосовского
Russian Federation, MoscowAlyona D. Solonina
Sechenov First Moscow State Medical University (Sechenov University)
Email: e.okisheva@gmail.com
ORCID iD: 0009-0007-3017-8327
студентка Института клинической медицины им. Н.В. Склифосовского
Russian Federation, MoscowAlexey V. Zhidilyaev
Sechenov First Moscow State Medical University (Sechenov University)
Email: e.okisheva@gmail.com
ORCID iD: 0000-0001-9420-3367
врач – травматолог-ортопед Клиники травматологии, ортопедии и патологии суставов
Russian Federation, MoscowAlexey V. Lychagin
Sechenov First Moscow State Medical University (Sechenov University)
Email: e.okisheva@gmail.com
ORCID iD: 0000-0002-2202-8149
д-р мед. наук, проф., зав. каф. травматологии, ортопедии и хирургии катастроф Института клинической медицины им. Н.В. Склифосовского
Russian Federation, MoscowVictor V. Fomin
Sechenov First Moscow State Medical University (Sechenov University)
Email: e.okisheva@gmail.com
ORCID iD: 0000-0002-2682-4417
чл.-кор. РАН, д-р мед. наук, проф., проректор по инновационной и клинической деятельности, зав. каф. факультетской терапии №1 Института клинической медицины им. Н.В. Склифосовского
Russian Federation, MoscowReferences
- Santana DC, Hadad MJ, Emara A, et al. Perioperative Management of Chronic Antithrombotic Agents in Elective Hip and Knee Arthroplasty. Medicina (Kaunas). 2021;57(2):188. doi: 10.3390/medicina57020188
- Середа А.П., Кочиш А.А., Черный А.А., и др. Эпидемиология эндопротезирования тазобедренного и коленного суставов и перипротезной инфекции в Российской Федерации. Травматология и ортопедия России. 2021;27(3):84-93 [Sereda AP, Kochish AA, Cherny AA, et al. Epidemiology of Hip And Knee Arthroplasty and Periprosthetic Joint Infection in Russian Federation. Traumatology and Orthopedics of Russia. 2021;27(3):84-93 (in Russian)]. doi: 10.21823/2311-2905-2021-27-3-84-93
- Parvizi J, Huang R, Rezapoor M, et al. Individualized Risk Model for Venous Thromboembolism After Total Joint Arthroplasty. J Arthroplasty. 2016;31(9 Suppl.):180-6. doi: 10.1016/j.arth.2016.02.077
- Божкова С.А., Тихилов Р.М., Андрияшкин В.В., и др. Профилактика, диагностика и лечение тромбоэмболических осложнений в травматологии и ортопедии: методические рекомендации. Травматология и ортопедия России. 2022;28(3):136-66 [Bozhkova SA, Tikhilov RM, Andriyashkin VV, et al. Prevention, Diagnosis and Treatment of Thromboembolic Complications in Traumatology and Orthopedics: Methodological Guidelines. Traumatology and Orthopedics of Russia. 2022;28(3):136-66 (in Russian)]. doi: 10.17816/2311-2905-1993
- Решетько О.В., Соколов А.В., Фурман Н.В. Анализ антитромботической терапии фибрилляции предсердий в международных и российских регистрах. Качественная клиническая практика. 2019;1:83-96 [Reshetko OV, Sokolov AV, Furman NV. Analysis of antithrombotic therapy of atrial fibrillation in international and Russian registries. Kachestvennaya klinicheskaya praktika. 2019;1:83-96 (in Russian)]. doi: 10.24411/2588-0519-2019-10066
- Tsukada S, Kurosaka K, Nishino M, et al. A Strategy of Continued Antiplatelet Agents, Vitamin K Antagonists, and Direct Oral Anticoagulants Throughout the Perioperative Period of Total Knee Arthroplasty in Patients Receiving Chronic Antithrombotic Therapy. JB JS Open Access. 2019;4(3):e0057.1-6. doi: 10.2106/JBJS.OA.18.00057
- Ferguson RJ, Palmer AJ, Taylor A, et al. Hip replacement. Lancet. 2018;392(10158):1662-61. doi: 10.1016/S0140-6736(18)31777-X
- Purdy JC, Shatzel JJ. The hematologic consequences of obesity. Eur J Haematol. 2021;106(3):306-19. doi: 10.1111/ejh.13560
- Espindola R, Vella V, Benito N, et al. Preoperative and perioperative risk factors, and risk score development for prosthetic joint infection due to Staphylococcus aureus: a multinational matched case-control study. Clin Microbiol Infect. 2022;28(10):1359-66. doi: 10.1016/j.cmi.2022.05.010
- Окишева Е.А., Миронова О.Ю., Мадоян М.Д., и др. Медикаментозная терапия сердечно-сосудистых заболеваний у пациентов, госпитализированных для планового эндопротезирования крупных суставов: анализ реальной клинической практики. Consilium Medicum. 2023;25(1):34-8 [Okisheva EA, Mironova OI, Madoyan MD, et al. Cardiovascular therapy in patients hospitalized for elective large joint arthroplasty: real-world practice review. Consilium Medicum. 2023;25(1):34-8 (in Russian)]. doi: 10.26442/20751753.2023.1.202097
- Halvorsen S, Mehilli J, Cassese S, et al. 2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery. Eur Heart J. 2022;43(39):3826-924. doi: 10.1093/eurheartj/ehac270
- CRISTAL Study Group; Sidhu VS, Kelly TL, Pratt N, et al. Effect of Aspirin vs Enoxaparin on Symptomatic Venous Thromboembolism in Patients Undergoing Hip or Knee Arthroplasty: The CRISTAL Randomized Trial. JAMA. 2022;328(8):719-27. doi: 10.1001/jama.2022.13416
- Ashkenazi I, Schermann H, Gold A, et al. Is continuation of anti-platelet treatment safe for elective total hip arthroplasty patients? Arch Orthop Trauma Surg. 2020;140(12):2101-17. doi: 10.1007/s00402-020-03629-7
- Meier R, Marthy R, Saely CH, et al. Comparison of preoperative continuation and discontinuation of aspirin in patients undergoing total hip or knee arthroplasty. Eur J Orthop Surg Traumatol. 2016;26(8):921-2. doi: 10.1007/s00590-016-1830-7
Supplementary files
